Spravto
Spravato
SPRAVATO® (esketamine) CIII Nasal Spray is the only FDA-approved treatment used as monotherapy or in conjunction with an oral antidepressant for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.
Administration Information
To ensure safe and appropriate use, SPRAVATO® nasal spray is administered only at REMS-certified treatment centers
After taking SPRAVATO®, patients are monitored and evaluated by a healthcare provider for at least 2 hours until patients are safe to leave
Treatment involves multiple sessions, with the frequency and duration varying depending on the individual patient's needs and the specific indication.
Once per week or every 2 weeks
Potential Side Effects
SPRAVATO® may cause increased blood pressure, sedation or loss of consciousness. In some cases, patients may display diminished or less apparent breathing. Other side effects may occur.
See a full list of serious side effects on the drug manufacturer website.
Helpful Resources
What is Spravato?
Patient Support
Before you attend your first appointment at Sage Elevate, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices, Patient Rights and Responsibilities, and Appointment Lateness and Cancelation are for reference only. Please contact us if you have any questions!
